Novartis: new data confirms profile of cholesterol drug
(CercleFinance.com) - Switzterland's Novartis said that new data for its cholesterol-lowering drug inclisiran confirmed the profile of the drug, for which it is currently seeking approval.
Novartis said Phase III data showed high efficacy, tolerability and safety over 17 months on twice-yearly subcutaneous dosing in 2,300 patients, of which 1,164 were on inclisiran.
It said data also demontsrated that 99% of patients treated with inclisiran showed placebo-adjusted reduction in low-density lipoprotein cholesterol (LDL-C) of more than 30%.
Novartis said inclisiran is currently being reviewed by the US Food and Drug Administration and the European Medicines Agency for the treatment of primary hyperlipidemia in adults who have elevated LDL-C.
Copyright (c) 2020 CercleFinance.com. All rights reserved.
Novartis said Phase III data showed high efficacy, tolerability and safety over 17 months on twice-yearly subcutaneous dosing in 2,300 patients, of which 1,164 were on inclisiran.
It said data also demontsrated that 99% of patients treated with inclisiran showed placebo-adjusted reduction in low-density lipoprotein cholesterol (LDL-C) of more than 30%.
Novartis said inclisiran is currently being reviewed by the US Food and Drug Administration and the European Medicines Agency for the treatment of primary hyperlipidemia in adults who have elevated LDL-C.
Copyright (c) 2020 CercleFinance.com. All rights reserved.